Literature DB >> 18578541

Lipid-derived aldehydes accelerate light chain amyloid and amorphous aggregation.

Jorge Nieva1, Asher Shafton, Laurence J Altobell, Sangeetha Tripuraneni, Joseph K Rogel, Anita D Wentworth, Richard A Lerner, Paul Wentworth.   

Abstract

Antibody light chain (LC) aggregation in vivo leads to the systemic deposition of Ig light chain domains in the form of either amyloid fibrils (AL-amyloidosis) or amorphous deposits, light-chain deposition disease (LCDD), in mainly cardiac or renal tissue and is a pathological condition that is often fatal. Molecular factors that may contribute to the propensity of LCs to aggregate in vivo, such as the protein primary structure or local environment, are intensive areas of study. Herein, we show that the aggregation of a human antibody kappa-(kappa-MJM) and lambda-(lambda-L155) light chain (1 mg/mL) can be accelerated in vitro when they are incubated under physiologically relevant conditions, PBS, pH 7.4 and 37 degrees C, in the presence of a panel of biologically relevant lipid-derived aldehydes, 4-hydroxynonenal (4-HNE), malondialdehyde (MDA), glyoxal (GLY), atheronal-A (KA), and atheronal-B (ALD). Thioflavin-T (ThT) and Congo Red (CR) binding assays coupled with turbidity studies reveal that this aldehyde-induced aggregation can be associated with alteration of protein secondary structure to an increased beta-sheet conformation. We observed that the nature of the conformational change is primarily dependent upon the lipidic aldehyde studied, not the protein sequence. Thus, the cholesterol 5,6-secosterols, KA and ALD, cause an amorphous-type aggregation which is ThT and CR negative for both the kappa-MJM and lambda-L155 light chains, whereas 4-HNE, MDA, and GLY induce aggregates that bind both ThT and CR. TEM analysis revealed that amyloid fibrils were formed during the 4-HNE-mediated aggregation of kappa-MJM and lambda-L155 light chains, whereas ALD-induced aggregates of these LCs where amorphous in nature. Kinetic profiles of LC aggregation reveal clear differences between the aldehydes, KA and ALD, causing a classic nucleated polymerization-type aggregation, with a lag phase (of approximately 150 h) followed by a growth phase that plateaus, whereas 4-HNE, MDA, and GLY trigger a seeded-type aggregation process that has no lag phase. In-depth studies of the 4-HNE-accelerated aggregation of kappa-MJM and lambda-L155 reveal a clear aldehyde concentration dependence and a process that can be inhibited by the naturally occurring osmolyte trimethylamine N-oxide (TMAO). Given these data, we feel our recently discovered paradigm of inflammatory aldehyde-induced protein misfolding may now extend to LC aggregation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18578541     DOI: 10.1021/bi800333s

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  15 in total

1.  Two disaccharides and trimethylamine N-oxide affect Abeta aggregation differently, but all attenuate oligomer-induced membrane permeability.

Authors:  Wei Qi; Aming Zhang; Theresa A Good; Erik J Fernandez
Journal:  Biochemistry       Date:  2009-09-22       Impact factor: 3.162

2.  Adduction of cholesterol 5,6-secosterol aldehyde to membrane-bound myelin basic protein exposes an immunodominant epitope.

Authors:  Natalie K Cygan; Johanna C Scheinost; Terry D Butters; Paul Wentworth
Journal:  Biochemistry       Date:  2011-02-28       Impact factor: 3.162

3.  Cholesterol secosterol aldehydes induce amyloidogenesis and dysfunction of wild-type tumor protein p53.

Authors:  Jorge Nieva; Byeong-Doo Song; Joseph K Rogel; David Kujawara; Lawrence Altobel; Alicia Izharrudin; Grant E Boldt; Rajesh K Grover; Anita D Wentworth; Paul Wentworth
Journal:  Chem Biol       Date:  2011-07-29

Review 4.  New views on cellular uptake and trafficking of manufactured nanoparticles.

Authors:  Lennart Treuel; Xiue Jiang; Gerd Ulrich Nienhaus
Journal:  J R Soc Interface       Date:  2013-02-20       Impact factor: 4.118

5.  Effects of diets enriched in linoleic acid and its peroxidation products on brain fatty acids, oxylipins, and aldehydes in mice.

Authors:  Christopher E Ramsden; Marie Hennebelle; Susanne Schuster; Gregory S Keyes; Casey D Johnson; Irina A Kirpich; Jeff E Dahlen; Mark S Horowitz; Daisy Zamora; Ariel E Feldstein; Craig J McClain; Beverly S Muhlhausler; Maria Makrides; Robert A Gibson; Ameer Y Taha
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2018-07-25       Impact factor: 4.698

6.  Probing lipid-protein adduction with alkynyl surrogates: application to Smith-Lemli-Opitz syndrome.

Authors:  Katherine Windsor; Thiago C Genaro-Mattos; Hye-Young H Kim; Wei Liu; Keri A Tallman; Sayuri Miyamoto; Zeljka Korade; Ned A Porter
Journal:  J Lipid Res       Date:  2013-07-04       Impact factor: 5.922

7.  Cholesterol secosterol adduction inhibits the misfolding of a mutant prion protein fragment that induces neurodegeneration.

Authors:  Johanna C Scheinost; Daniel P Witter; Grant E Boldt; John Offer; Paul Wentworth
Journal:  Angew Chem Int Ed Engl       Date:  2009       Impact factor: 15.336

8.  The ratio of cholesterol 5,6-secosterols formed from ozone and singlet oxygen offers insight into the oxidation of cholesterol in vivo.

Authors:  Anita D Wentworth; Byeong-Doo Song; Jorge Nieva; Asher Shafton; Sangeetha Tripurenani; Paul Wentworth
Journal:  Chem Commun (Camb)       Date:  2009-04-16       Impact factor: 6.222

Review 9.  Evidence of endothelial dysfunction in the development of Alzheimer's disease: Is Alzheimer's a vascular disorder?

Authors:  Rory J Kelleher; Roy L Soiza
Journal:  Am J Cardiovasc Dis       Date:  2013-11-01

10.  Rotenone Induces the Formation of 4-Hydroxynonenal Aggresomes. Role of ROS-Mediated Tubulin Hyperacetylation and Autophagic Flux Disruption.

Authors:  Luis Bonet-Ponce; Sara Saez-Atienzar; Carmen da Casa; Javier Sancho-Pelluz; Jorge M Barcia; Natalia Martinez-Gil; Eduardo Nava; Joaquín Jordan; Francisco J Romero; Maria F Galindo
Journal:  Mol Neurobiol       Date:  2015-11-12       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.